Huang Wei, Luo Jiayu, Wen Jianbo, Jiang Mingjun
Department of Cardiothoracic Surgery, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Department of Oncology, No.906 Hospital of People's Liberation Army, Ningbo, China.
Front Surg. 2022 Jun 30;9:898304. doi: 10.3389/fsurg.2022.898304. eCollection 2022.
The relationship between systemic immune inflammation index (SII) and the prognosis of cancer has always been a subject of intense interest. However, the prognostic value of SII in non-small cell lung cancer (NSCLC) patients remains a controversial topic.
To evaluate the effect of SII index on prognosis of NSCLC.
We conducted a comprehensive search of PubMed, EMBASE, and the Cochrane Library databases to determine correlation between SII index, clinicopathological features, overall survival (OS), and progression-free survival (PFS). Odds ratio (ORs) and 95% confidence interval (CIs) were used to assess the connection between SII and clinicopathological parameters, and HRs and 95% CIs were used to assess the connection between SII and survival.
Seventeen studies with 8,877 cases were included in the analysis. Compared with NSCLC patients with low SII level, patients with NSCLC with high SII level had a poor OS (HR = 1.75, 95% CI, 1.50-2.00; < 0.001) and had a poor PFS (HR = 1.61, 95% CI, 1.25-1.96; < 0.001). In addition, patients with higher pathological stage (II-III) had higher SII levels (OR = 2.32, 95% CI, 2.06-2.62; < 0.001).
The SII index is a promising prognostic biomarker for NSCLC and may help clinicians choose appropriate NSCLC treatments.
全身免疫炎症指数（SII）与癌症预后之间的关系一直是人们密切关注的话题。然而，SII在非小细胞肺癌（NSCLC）患者中的预后价值仍是一个有争议的话题。
评估SII指数对NSCLC预后的影响。
我们对PubMed、EMBASE和Cochrane图书馆数据库进行了全面检索，以确定SII指数、临床病理特征、总生存期（OS）和无进展生存期（PFS）之间的相关性。采用比值比（OR）和95%置信区间（CI）评估SII与临床病理参数之间的关联，采用风险比（HR）和95%CI评估SII与生存率之间的关联。
分析纳入了17项研究，共8877例病例。与SII水平低的NSCLC患者相比，SII水平高的NSCLC患者OS较差（HR = 1.75，95%CI，1.50 - 2.00；P < 0.001），PFS也较差（HR = 1.61，95%CI，1.25 - 1.96；P < 0.001）。此外，病理分期较高（II - III期）的患者SII水平较高（OR = 2.32，95%CI，2.06 - 2.62；P < 0.001）。
SII指数是一种有前景的NSCLC预后生物标志物，可能有助于临床医生选择合适的NSCLC治疗方案。
